Xarelto, an anticoagulant medication, is available in a 20mg dosage. Generic versions of Xarelto are anticipated to become available in the United States.
When is the Xarelto patent expected to expire?
The primary patents protecting Xarelto (rivaroxaban) are slated to expire in late 2024. Specifically, U.S. Patent No. 7,351,841, a key patent for the drug, is set to expire on December 9, 2024. Another related patent, U.S. Patent No. 8,778,951, is set to expire on July 3, 2026. [1]
What happens when Xarelto goes generic?
Once Xarelto's patents expire and generic versions enter the market, the cost of the medication is expected to decrease significantly. This often leads to increased accessibility for patients and greater competition among manufacturers. [2]
Who makes the generic version of Xarelto?
As of late 2023, several pharmaceutical companies have filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) seeking approval to market generic versions of Xarelto. These companies include Accord Healthcare, Amneal Pharmaceuticals, Apotex, Aurobindo Pharma, Dr. Reddy's Laboratories, Hetero Labs, Hikma Pharmaceuticals, Mylan (now Viatris), Novel Laboratories, Pragma, Sandoz, Teva Pharmaceuticals, and Zydus Lifesciences. [1][3] The specific companies that will successfully launch generic rivaroxaban products will depend on FDA approval and their strategic market entry plans.
How do generic Xarelto prices compare?
While specific pricing for generic rivaroxaban is not yet established as it is not currently on the market, generic drugs are typically priced substantially lower than their brand-name counterparts. For example, after the launch of generic versions of other anticoagulant medications, prices have fallen by as much as 85%. [2]
What is rivaroxaban?
Rivaroxaban, the active ingredient in Xarelto, is a direct factor Xa inhibitor. It works by preventing blood clot formation. It is prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). [4]
What are the potential risks of taking Xarelto?
The most significant risk associated with Xarelto, like other anticoagulants, is bleeding. This can range from minor bruising to life-threatening hemorrhages. Patients taking Xarelto should be aware of signs of bleeding, such as unusual or severe bruising, nosebleeds, bleeding gums, blood in urine or stool, or prolonged bleeding from cuts. [4]
Sources:
1. https://drugpatentwatch.com/drug/rivaroxaban
2. DrugPatentWatch.com (general knowledge of generic drug market dynamics)
3. https://www.drugpatentwatch.com/blog/us-patent-expiry-of-rivaroxaban-xarelto
4. FDA.gov (general drug information)